• QuestionOfTheWeek Banners x
  • 19 SSO 014 Digital Banners MembershipBanner 1150x135 v5
  • ExpertEd Brand Refresh 1150x135 Surgonc Podcast Banner
  • SSO Mobile App Website Top 1150x135 Banner

ADVERTISEMENT

Global Header

Annals of Surgical Oncology

HIGHLIGHTED ARTICLES FROM ANNALS OF SURGICAL ONCOLOGY

Weekly Update

Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group

Management of Primary Retroperitoneal Sarcoma in the Adult

May 19, 2022

https://doi.org/10.1245/s10434-021-09654-z

Citation:

Swallow, C.J., Strauss, D.C., Bonvalot, S. et al. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. Ann Surg Oncol 28, 7873–7888 (2021).

Synopsis: Consensus statements for the optimal management of patients with primary retroperitoneal sarcoma were updated in view of new understanding of histologic subtype-specific biology and therapeutic response. Patients should undergo investigation and treatment by an experienced multidisciplinary team at a sarcoma referral center.

Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)

May 19, 2022

https://doi.org/10.1245/s10434-022-11413-7

Citation:

Redegalli, M., Schiavo Lena, M., Cangi, M.G. et al. Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC). Ann Surg Oncol 29, 3492–3502 (2022).

Synopsis:  Pancreatic ductal adenocarcinoma (PDAC) tumor morphology is significantly altered by NACT. Perineural invasion, lymph node ratio, and stroma to neoplasia ratio are prognostic factors for neoadjuvant chemotherapy (NACT)-treated PDAC patients. The semi quantitative pathologic prognostic index predicts patients’ outcome after NACT followed by surgery.

Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal

Listen to the ASO's new podcast, Speaking of SurgOnc®

Speaking of SurgOnc Speaking of SurgOnc® is a podcast brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology (SSO).

The series is hosted by ASO Deputy Editor Dr. Frederick L. (Rick) Greene, who will expand upon ideas from articles published in the Annals. Once a month, Dr. Greene will interview authors and leading experts in surgical oncology.

Listen to the podcast here.

ASO is the journal of choice of surgical oncologists and cancer multidisciplinary teams worldwide regarding surgical oncology research and education, and benefits surgeons, oncologists, hematologists, radiologists, general practitioners, pathologists, researchers, academicians, and other clinical professionals interested in all aspects of the surgical treatment of cancer. ASO strives to improve the practice environment in which high-quality surgical oncology care is delivered, to enhance the quality of life and survival of the surgical patient with cancer.

Join the conversation! Follow the journal on Twitter and Facebook. Help to expand the reach of the journal to support the research and practice needs of surgical oncologists and their patients.

Scroll to Top